Giving patients with advanced stomach or esophageal cancer a transplant of gut bacteria from overweight people did not help with the weight loss and poor appetite caused by the cancer. In a small study, patients who got these bacteria did no better than patients who got a treatment with their own bacteria.
See the scientific wording
Allogenic fecal microbiota transplantation (FMT) from overweight or obese donors, administered prior to first-line palliative chemotherapy, does not improve cancer-related cachexia symptoms, including appetite (satiety), weight, and body composition, in patients with metastatic HER2-negative gastroesophageal cancer, based on a randomized, double-blind, placebo-controlled phase II trial that found no significant differences between allogenic and autologous FMT.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2021
The study gave some cancer patients bacteria from an overweight person and others their own bacteria, and found no difference in appetite or weight loss, so the claim that this treatment doesn't help cachexia is true.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Giving patients new gut bacteria changes the mix of bacteria in their gut, but these changes do not alter the body's harmful immune and energy-use signals enough. The cancer still causes inflammation that makes patients lose appetite and muscle, so the treatment does not help with these symptoms.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Giving patients with advanced stomach or esophageal cancer a transplant of gut bacteria from overweight people did not help with the weight loss and poor appetite caused by the cancer. In a small study, patients who got these bacteria did no better than patients who got a treatment with their own bacteria.
Mechanism
1 studyThe treatment changes the types of bacteria in the gut, but this change is not strong enough to fix the body's inflammation and weight loss problems caused by the cancer. So patients still lose their appetite and muscle, and the treatment does not help with their cachexia symptoms.
Giving patients new gut bacteria changes the mix of bacteria in their gut, but these changes do not alter the body's harmful immune and energy-use signals enough. The cancer still causes inflammation that makes patients lose appetite and muscle, so the treatment does not help with these symptoms.
Fecal microbiota transplantation introduces donor bacterial species that engraft and proliferate in the recipient's gut, significantly altering the overall microbial community composition.
The altered gut microbial community produces different metabolites and signals, but in patients with advanced gastroesophageal cancer, these changes are insufficient to reduce the chronic systemic inflammation and catabolic mediators that drive cachexia.
Because the pro-inflammatory and catabolic state persists, appetite remains suppressed, and fat and muscle breakdown continues unabated, resulting in no improvement in weight or body composition.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study gave some cancer patients bacteria from an overweight person and others their own bacteria, and found no difference in appetite or weight loss, so the claim that this treatment doesn't help cachexia is true.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Randomized Controlled Trials Evaluating Fecal Microbiota Transplantation for Cancer Cachexia
Comprehensive search of databases for RCTs comparing allogenic FMT to placebo or autologous FMT in cancer patients with cachexia, pooling data on appetite, weight, and body composition.
Large-Scale Double-Blind Randomized Placebo-Controlled Trial of Allogenic Fecal Microbiota Transplantation vs Autologous for Cachexia in Metastatic Gastroesophageal Cancer
Randomize 200+ patients with metastatic HER2-negative gastroesophageal cancer receiving first-line chemotherapy to receive allogenic FMT or autologous FMT (or placebo) before treatment; measure appetite, weight, body composition at baseline and multiple follow-ups over 12 weeks.
Prospective Cohort Study of Fecal Microbiota Transplantation in Cancer Patients and Cachexia Outcomes
Follow patients with gastroesophageal cancer who receive allogenic FMT as part of routine care versus those who don't, tracking cachexia indicators over months, controlling for confounders.
Retrospective Case-Control Study Comparing Cachexia Outcomes in Patients Who Received Allogenic FMT Versus Autologous FMT
Identify cases of improved cachexia and controls without improvement, then look back at medical records to determine if they received allogenic or autologous FMT.
Animal Model Study Testing the Effect of Donor Microbiota on Cancer-Induced Cachexia
Use mice with cancer-induced cachexia, transplant fecal microbiota from overweight humans or mice, measure weight, appetite, muscle mass, and inflammatory markers.